Glaukos (GKOS) Receives Daily News Impact Score of 0.25

Press coverage about Glaukos (NYSE:GKOS) has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Glaukos earned a daily sentiment score of 0.25 on Accern’s scale. Accern also assigned news headlines about the medical instruments supplier an impact score of 45.7896481892371 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Several equities research analysts have recently issued reports on GKOS shares. Cantor Fitzgerald set a $48.00 price objective on Glaukos and gave the company a “buy” rating in a research note on Wednesday, January 10th. BMO Capital Markets reissued a “buy” rating on shares of Glaukos in a research note on Monday, December 11th. Zacks Investment Research raised Glaukos from a “sell” rating to a “hold” rating in a research note on Monday, November 13th. Finally, Stephens reissued an “overweight” rating and set a $40.00 price target (down from $47.00) on shares of Glaukos in a research note on Monday, November 13th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Glaukos has a consensus rating of “Buy” and an average price target of $44.86.

Shares of Glaukos (NYSE:GKOS) opened at $28.55 on Friday. Glaukos has a one year low of $23.08 and a one year high of $52.49. The stock has a market capitalization of $1,023.83, a P/E ratio of -713.57, a P/E/G ratio of 42.93 and a beta of 1.02.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.04 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.02) by $0.06. The firm had revenue of $40.41 million during the quarter, compared to analyst estimates of $38.69 million. Glaukos had a positive return on equity of 3.50% and a negative net margin of 0.64%. Glaukos’s quarterly revenue was up 36.6% compared to the same quarter last year. During the same period last year, the company earned $0.03 EPS. equities analysts anticipate that Glaukos will post -0.03 EPS for the current year.

In other news, CFO Joseph E. Gilliam bought 2,100 shares of the firm’s stock in a transaction on Wednesday, November 22nd. The stock was acquired at an average cost of $23.84 per share, with a total value of $50,064.00. Following the transaction, the chief financial officer now directly owns 102,100 shares in the company, valued at approximately $2,434,064. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 16.40% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Week Herald and is owned by of Week Herald. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at

Glaukos Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Insider Buying and Selling by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with's FREE daily email newsletter.

Leave a Reply